📣 VC round data is live. Check it out!
- Public Comps
- Provectus
Provectus Valuation Multiples
Discover revenue and EBITDA valuation multiples for Provectus and similar public comparables like Teneo AI, Insig AI, Substrate Artificial, Lighton and more.
Provectus Overview
About Provectus
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes (HXs). Its HX molecule is named rose bengal sodium. The company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of its current clinical development programs and the preclinical formulations of its current drug discovery programs.
Founded
2002
HQ

Employees
6
Website
Financials (FY)
EV
$30M
Valuation Multiples
Start free trialProvectus Financials
Provectus reported last fiscal year revenue of — and negative EBITDA of ($5M).
In the same fiscal year, Provectus generated ($5M) in EBITDA losses and had net loss of ($6M).
Provectus P&L
In the most recent fiscal year, Provectus reported revenue of — and EBITDA of ($5M).
Provectus is unprofitable as of last fiscal year, with EBITDA margin of — and net margin of —.
Financial data powered by Morningstar, Inc.
Provectus Stock Performance
Provectus has current market cap of $27M, and enterprise value of $30M.
Provectus' stock price is $0.06.
Provectus has an EPS (earnings per share) of $-0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $30M | $27M | 0.0% | — | — | — | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialProvectus Valuation Multiples
Provectus trades at (5.6x) EV/EBITDA.
Provectus Financial Valuation Multiples
As of May 10, 2026, Provectus has market cap of $27M and EV of $30M.
Provectus has a P/E ratio of (4.9x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Provectus Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Provectus Margins & Growth Rates
Provectus Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Provectus Operational KPIs
Provectus' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Provectus Competitors
Provectus competitors include Teneo AI, Insig AI, Substrate Artificial, Lighton, Datrix, Helport AI, Satsuma Technology, OODA AI, Rocket Doctor AI and Ayfie International.
Most Provectus public comparables operate across Pure-Play AI Software and Generative AI.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 5.9x | — | (20.0x) | — | |||
| 39.7x | — | (3.5x) | — | |||
| 1.6x | — | 2.4x | — | |||
| 20.2x | 9.0x | (5.4x) | (4.2x) | |||
| 1.8x | 2.5x | 23.0x | 16.3x | |||
| 1.1x | — | 5.6x | — | |||
| 123017.6x | — | (173.8x) | — | |||
| 3.9x | — | (1.1x) | — | |||
This data is available for Pro users. Sign up to see all Provectus competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Provectus
| When was Provectus founded? | Provectus was founded in 2002. |
| Where is Provectus headquartered? | Provectus is headquartered in United States. |
| How many employees does Provectus have? | As of today, Provectus has over 6 employees. |
| Is Provectus publicly listed? | Yes, Provectus is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Provectus? | Provectus trades under PVCT ticker. |
| When did Provectus go public? | Provectus went public in 1997. |
| Who are competitors of Provectus? | Provectus main competitors include Teneo AI, Insig AI, Substrate Artificial, Lighton, Datrix, Helport AI, Satsuma Technology, OODA AI, Rocket Doctor AI, Ayfie International. |
| What is the current market cap of Provectus? | Provectus' current market cap is $27M. |
| Is Provectus profitable? | No, Provectus is not profitable. |
| How many companies Provectus has acquired to date? | Provectus hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Provectus has invested to date? | Provectus hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Provectus
Lists including Provectus
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.